<p>Investors looking for exposure to the COVID-19 vaccine market may naturally lean toward Moderna (NASDAQ:MRNA), which developed mRNA-1273, and Pfizer (NYSE:PFE), which developed BNT162b2 in collaboration with BioNTech. These companies were the first to earn Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for their respective products.</p>